23 recruiting, 12 unknown, 11 active not recruiting, 11 completed. 44 Phase 2, 17 Phase 3, 11 Phase 1, 4 Not applicable, 2 Phase 4.
Follow Platinum Compounds: new trials by email Literature Review of Platinum Compounds trials Research Report on Platinum Compounds
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study Firmonertinib, Platinum-based chemotherapy - Lung Adenocarcinoma, Stage III Lung Cancer | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 27 | 2026-11-01 | 2026-10-16 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor - Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Henan Cancer Hospital | 400 | 2026-08-20 | 2026-08-21 | |
| Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platinum-based chemotherapy - Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Hunan Province Tumor Hospital | 186 | 2026-08-12 | 2026-08-13 |
| Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer Toripalimab (240mg day1, Q3W*3cycle), Diphenhydramine, Platinum-based chemotherapy - NSCLC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-06-30 | 2026-06-12 |
| Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Henan Cancer Hospital | 1044 | 2026-06-16 | 2026-07-31 |
| Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer Camrelizumab, Platinum-based Chemotherapy plus PD-1 inhibitor, De-escalated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 180 | 2026-06-12 | 2026-08-28 |
| Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer Iparomlimab and Tuvonralimab combined with Platinum-Based Chemotherapy (Pemetrexed/Carboplatin for Non-squamous; Nab-paclitaxel/Carboplatin for Squamous) - Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging | Not applicable | Not yet recruiting | Tang-Du Hospital | 28 | 2026-05-01 | 2026-04-20 |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 42 | 2026-04-20 | 2026-06-01 |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) RC148 plus Carboplatin and Paclitaxel, Tislelizumab plus Carboplatin and Paclitaxel - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | RemeGen Co., Ltd. | 574 | 2026-04-03 | 2026-07-14 |
| SYS6090 Combination Therapy in Advanced Lung Cancer SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel - Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 596 | 2026-02-28 | 2026-03-16 |
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy - Ovarian Cancer, Ovarian Carcinoma, Recurrent | Phase 2 | Recruiting | Yonsei University | 116 | 2026-02-26 | 2026-04-20 |
| Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) Tislelizumab + platinum-based chemotherapy, Tislelizumab + platinum-based chemotherapy + focal radiotherapy - Non-Small Cell Lung Cancer | Phase 4 | Recruiting | Fujian Cancer Hospital | 60 | 2026-01-15 | 2026-01-06 |
| Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma Sintilimab plus nab-paclitaxel and platinum-based chemotherapy, Radical surgery combined with radiotherapy or chemoradiotherapy - Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC) | Phase 3 | Recruiting | Qunxing Li,MD | 104 | 2026-01-01 | 2026-01-28 |
| RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) Secondary cytoreductive surgery, Platinum Based Chemotherapy - Ovarian Cancer Recurrent, Platinum Sensitive Ovarian Cancer | Phase 2 | Not yet recruiting | Asan Medical Center | 160 | 2025-12-15 | 2025-12-19 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer SHR-8068，adebelizumab and platinum-based chemotherapy, tislelizumab, and platinum-based chemotherapy - Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 460 | 2025-10-22 | 2025-11-18 |
| Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma Capecitabine and Oxaliplatin, Fluorouracil, Leucovorin Calcium, and Oxaliplatin - Metastatic Colorectal Carcinoma (mCRC) | Not applicable | Enrolling by invitation | Allama Iqbal Medical College | 248 | 2025-09-01 | 2026-01-12 |
| Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy, RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy - NSCLC (Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Avistone Pharmaceutical（Ningbo）Co., LTD. | 108 | 2025-08-08 | 2025-07-25 |
Showing 20 of 80. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (35) · Lung Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (7) · Esophageal Neoplasms (6) · Ovarian Neoplasms (6) · Head and Neck Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Adenocarcinoma of Lung (2) · Carcinoma, Squamous Cell (2) · Esophageal Squamous Cell Carcinoma (2) · Fallopian Tube Neoplasms (2) · Retinoblastoma (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2)
Henan Cancer Hospital (4) · Bristol-Myers Squibb (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Tang-Du Hospital (3) · Fujian Cancer Hospital (2) · GlaxoSmithKline (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Hoffmann-La Roche (2) · Hunan Province Tumor Hospital (2) · Institut Curie (2) · Regeneron Pharmaceuticals (2) · Sun Yat-sen University (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · University Health Network, Toronto (2) · AIO-Studien-gGmbH (1)
China (32) · United States (20) · France (14) · Spain (14) · Italy (10) · Canada (9) · Germany (9) · United Kingdom (9) · Australia (7) · Belgium (6) · Israel (6) · South Korea (6) · Austria (5) · Brazil (5) · Japan (5)
Adrian Sacher, M.D. (1) · Aldo Perfetti, MD (1) · Amit Oza, M.D. (1) · Anne C Chiang (1) · Anne-Isabelle Bertozzi-Salamon, MD (1) · Bradford Perez, MD (1) · Carole Coze, MD (1) · Catherine Devoldere, MD (1) · Celine De Bouyn-Icher, MD (1) · Changming Huang, Professor (1) · Christophe Piguet, MD (1)
PMID 10089184, PMID 11091234, PMID 11223832, PMID 11289756, PMID 11712875, PMID 11754382, PMID 1334988, PMID 15783049, PMID 16003309, PMID 16643334, PMID 17058319, PMID 18095269, PMID 18656040, PMID 18685899, PMID 20113944, PMID 20610241, PMID 20650686, PMID 21336514, PMID 21573742, PMID 22752074, PMID 23018280, PMID 24399492, PMID 24826062, PMID 32183229, PMID 34439284, PMID 35470301, PMID 37643382, PMID 37689979, PMID 38095056, PMID 38980664, PMID 39054462, PMID 39836372, PMID 39892382, PMID 40367097, PMID 40532178, PMID 40682106, PMID 40898159, PMID 8180768
2023 (3), 2017 (2), 2019 (2), U10CA180888 (1), UM1CA186688 (1)